Epigenomics AG | Ownership

Companies that own Epigenomics AG

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
CM-CIC Asset Management SA
792,474
3.3%
42,474
0.04%
12/31/2017
Oddo BHF Asset Management SAS
668,286
2.78%
-31,247
0.02%
07/24/2017
Discover Capital GmbH
500,000
2.08%
150,000
0.24%
12/31/2017
Aramea Asset Management AG
275,000
1.14%
275,000
0.18%
09/30/2017
Amundi Asset Management SA (Investment Management)
126,848
0.53%
0
0%
01/31/2018
CAPFI DELEN Asset Management SA
75,000
0.31%
0
0%
06/29/2018
Union Investment Privatfonds GmbH
59,365
0.25%
-59,051
0%
03/31/2018
Matejka & Partner Asset Management GmbH
50,000
0.21%
-201,815
0.08%
12/31/2017
SSgA Funds Management, Inc.
9,284
0.04%
36
0%
09/06/2018
AcomeA SGR SpA
4,359
0.02%
-641
0%
10/31/2017

About Epigenomics

View Profile
Address
Geneststraße 5
Berlin Berlin 10829
Germany
Employees -
Website http://www.epigenomics.de
Updated 07/08/2019
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, and Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA. The comapny was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo Gut on April 30, 1997 and is headquartered in Berlin, Germany.